Illumina's Q2 Sales Rise 36 Percent on Sequencing Demand, 'Overall Improvement' in Array Sales
August 02, 2011
Illumina's Q2 Sales Rise 36 Percent on Sequencing Demand, 'Overall Improvement' in Array Sales
The firm credited "strong demand" for its next-gen-sequencing tools and restored growth in its array business, particularly for whole-genome genotyping chips for the spike in sales.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.